Nissen SE - Search Results

1

Risk of cardiovascular events associated with selective COX-2 inhibitors.

Mukherjee D, Nissen SE, Topol EJ. Mukherjee D, et al. Among authors: nissen se. JAMA. 2001 Aug 22-29;286(8):954-9. doi: 10.1001/jama.286.8.954. JAMA. 2001. PMID: 11509060 Review.

2

Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease.

Topol EJ, Nissen SE. Topol EJ, et al. Among authors: nissen se. Circulation. 1995 Oct 15;92(8):2333-42. doi: 10.1161/01.cir.92.8.2333. Circulation. 1995. PMID: 7554219 Review.

3

Recommendations for development and maintenance of competence in coronary interventional procedures. American College of Cardiology Cardiac Catheterization Committee.

Douglas JS Jr, Levin DC, Pepine CJ, Mullins CE, Block PC, Nissen SE, Brinker JA, Topol EJ, Johnson WL Jr, Ullyot DJ, et al. Douglas JS Jr, et al. Among authors: nissen se. J Am Coll Cardiol. 1993 Aug;22(2):629-31. doi: 10.1016/0735-1097(93)90078-f. J Am Coll Cardiol. 1993. PMID: 8335841 Free article. No abstract available.

4

Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution.

Mukherjee D, Nissen SE, Topol EJ. Mukherjee D, et al. Among authors: nissen se. Cleve Clin J Med. 2001 Nov;68(11):963-4. doi: 10.3949/ccjm.68.11.963. Cleve Clin J Med. 2001. PMID: 11718438 Free article. Review. No abstract available.

5

Lack of cardioprotective effect of naproxen.

Mukherjee D, Nissen SE, Topol EJ. Mukherjee D, et al. Among authors: nissen se. Arch Intern Med. 2002 Dec 9-23;162(22):2637; author reply 2638-9. doi: 10.1001/archinte.162.22.2637. Arch Intern Med. 2002. PMID: 12456255 No abstract available.

6

Prognostic value of myeloperoxidase in patients with chest pain.

Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Brennan ML, et al. Among authors: nissen se. N Engl J Med. 2003 Oct 23;349(17):1595-604. doi: 10.1056/NEJMoa035003. N Engl J Med. 2003. PMID: 14573731 Free article.

7

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Nissen SE, et al. JAMA. 2003 Nov 5;290(17):2292-300. doi: 10.1001/jama.290.17.2292. JAMA. 2003. PMID: 14600188 Clinical Trial.

8

In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis.

Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes DJ, Nissen SE. Aronow HD, et al. Among authors: nissen se. Arch Intern Med. 2003 Nov 24;163(21):2576-82. doi: 10.1001/archinte.163.21.2576. Arch Intern Med. 2003. PMID: 14638557

9

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Nissen SE, et al. JAMA. 2004 Mar 3;291(9):1071-80. doi: 10.1001/jama.291.9.1071. JAMA. 2004. PMID: 14996776 Clinical Trial.

10

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Nissen SE, et al. JAMA. 2004 Nov 10;292(18):2217-25. doi: 10.1001/jama.292.18.2217. JAMA. 2004. PMID: 15536108 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

555 results

Search Page